Vanda Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- $311.8M
- Introduction
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Open-Label Evaluation of Relapse Prevention in Patients With Schizophrenia
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06961968
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
- Conditions
- Insomnia Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 420
- Registration Number
- NCT06953869
- Locations
- 🇺🇸
Vanda Investigational Site, San Antonio, Texas, United States
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
- Conditions
- Idiopathic GastroparesisDiabetic GastroparesisGastroparesis
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06836557
- Locations
- 🇩🇪
Vanda Investigational Site, Leipzig, Germany
Evaluation of Efficacy and Safety of Milsaperidone As Adjunctive Therapy in Patients with Major Depressive Disorder
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06830044
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06804603
- Locations
- 🇺🇸
Vanda Investigational Site, Rochester, Minnesota, United States
Food Effect Study of VHX-896 in Healthy Volunteers
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06803290
- Locations
- 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
- Conditions
- Sleep Wake DisordersSleep Disorders, Circadian RhythmChronobiology DisordersGene Mutations and Other Alterations Nec
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT06701396
- Locations
- 🇹🇷
Vanda Investigational Site, Çankaya, Ankara, Turkey
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
- Conditions
- SchizophreniaBipolar I Disorder
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06494397
- Locations
- 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States
Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06323655
- Locations
- 🇨🇦
Vanda Investigational Site, Laval, Quebec, Canada
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT06296966
- Locations
- 🇺🇸
Vanda Investigational Site, Andover, Massachusetts, United States